Tyh1的个人主页 - 老虎社区

Tyh1

Tyh1

暂无个人介绍

IP属地：未知

11关注

2粉丝

0主题

0勋章

2021-08-03

$XPeng Inc.(XPEV)$$$$

2021-07-27

Ok

抱歉，原内容已删除

2021-07-22

Gyghhhhh

2 High-Risk, High-Reward Stocks That Could Go to the Moon

2021-06-29

$NIO Inc.(NIO)$[Miser] [Miser] [Miser]

2021-06-29

Waiting for below $20

2021-06-28

$NIO Inc.(NIO)$[Miser] $50 tonight

2021-06-28

giggle

抱歉，原内容已删除

2021-06-28

[Smile]

The Fed’s inflation view could drag the economy into recession, El-Erian warns

2021-06-24

[Glance]

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3586648044185069","uuid":"3586648044185069","gmtCreate":1623554020745,"gmtModify":1624547800483,"name":"Tyh1","pinyin":"tyh1","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":11,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":804335985,"gmtCreate":1627920967347,"gmtModify":1631889891272,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>$$$","listText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>$$$","text":"$XPeng Inc.(XPEV)$$$$","images":[{"img":"https://static.tigerbbs.com/72e0fa37cc7f2667fb941564466feb83","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804335985","isVote":1,"tweetType":1,"viewCount":131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":803999340,"gmtCreate":1627399466680,"gmtModify":1631889891276,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/803999340","repostId":"2154961091","repostType":2,"isVote":1,"tweetType":1,"viewCount":381,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172537894,"gmtCreate":1626965686918,"gmtModify":1631889891280,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"Gyghhhhh","listText":"Gyghhhhh","text":"Gyghhhhh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172537894","repostId":"2153755876","repostType":4,"repost":{"id":"2153755876","kind":"highlight","pubTimestamp":1626959340,"share":"https://www.laohu8.com/m/news/2153755876?lang=&edition=full","pubTime":"2021-07-22 21:09","market":"us","language":"en","title":"2 High-Risk, High-Reward Stocks That Could Go to the Moon","url":"https://stock-news.laohu8.com/highlight/detail?id=2153755876","media":"Motley Fool","summary":"Risk-averse investors may want to look elsewhere.","content":"<p>There is no such thing as a risk-free investment in the stock market (or anywhere else, for that matter). However, some carry more risks than others. Many investors choose to stay away from those companies that seem too much like longshots.</p>\n<p>But others actively seek out those stocks that the market characterizes as too risky, as the potential rewards are often mouthwatering. If you belong to the latter group, here are two stocks that are a bit on the risky side, but could deliver huge gains if their respective prospects pan out: <b>Planet 13 Holdings</b> (OTC:PLNH.F) and <b>Cassava Sciences</b> (NASDAQ:SAVA).</p>\n<p><img src=\"https://static.tigerbbs.com/74a895bc6e17c8f58a2b42d63ee986c8\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>PLNHF data by YCharts</p>\n<h3>1. Planet 13 Holdings</h3>\n<p>Wall Street analyst Owen Bennett recently called the U.S. marijuana industry a \"generational wealth opportunity.\" Whether you agree with the exact wording of this assessment or not, there is no denying that many pot stocks do offer massive growth potential. And among these companies, Planet 13 Holdings arguably has <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most innovative business models.</p>\n<p>The company isn't content with selling cannabis products. Instead, Planet 13 offers its customers a whole experience in its superstore, located on the popular Las Vegas Strip. Cannabis enthusiasts can witness firsthand the company's cannabis production process, purchase various marijuana products, and relax in the restaurant located right inside.</p>\n<p>With a growing number of people fully vaccinated against COVID-19, foot traffic and tourism in Las Vegas are picking up, and Planet 13 is benefiting. The pot company reported record monthly revenue of $9.7 million in March. It went on to beat that record in April when it racked up $10.7 million in revenue. It beat that record once again in May with monthly revenue of $11.2 million.</p>\n<p>Planet 13 recently opened another superstore in California, the largest U.S. state by population. The company has ambitions to open more of these cannabis-focused entertainment complexes in major cities in the U.S., including <a href=\"https://laohu8.com/S/NWY\">New York</a> <a href=\"https://laohu8.com/S/CHCO\">City</a>, <a href=\"https://laohu8.com/S/WASH\">Washington</a> D.C., and Miami.</p>\n<p>This master plan isn't guaranteed to work. The cannabis industry in the U.S. is very competitive, with several companies expanding their footprints across more than a dozen states. Some of these companies generate quarterly revenue and profits much higher than those of Planet 13. Also, opening these new stores in other states will cost money, and will come with additional expenses once they are operational.</p>\n<p>Management's goal of opening more than eight new superstores in the next five years might be doable, and the company is betting that these stores will see the same success as the <a href=\"https://laohu8.com/S/AONE.U\">one</a> in Las Vegas -- which is by no means a sure bet. Planet 13 remains a small-cap company with a market cap of just $1.2 billion, and that's after its shares soared by 184% in the past year.</p>\n<p>If Planet 13 goes on to execute its long-term plan, those who purchase this cannabis stock today will be glad they did so down the road.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F634051%2Fmature-person-sits-in-a-red-chair-in-front-of-a-large-window-contemplating-something-while-looking-at-a-tablet.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"465\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images</p>\n<h3>2. Cassava Sciences</h3>\n<p>Shares of clinical-stage biopharma company Cassava Sciences are up by a cool 3,285% in the past year. What's behind this performance? The drugmaker's leading pipeline candidate and investigational Alzheimer's disease (AD) drug, simufilam. This medicine has produced promising data in clinical trials. In a phase 2b study, the results of which Cassava Sciences announced in September 2020, simufilam was shown to improve several biomarkers of AD in patients with the disease.</p>\n<p>According to the company, \"the ability to improve&nbsp;multiple biomarkers from distinct biological pathways with one drug has never been shown before in patients with Alzheimer's disease.\" In early February the company also announced results of an interim analysis of an open-label study for simufilam. The medicine successfully improved AD patients' cognition and behavior.</p>\n<p>Even though these results are encouraging in and of themselves, investors have also taken interest in Cassava Sciences because of the recent controversial approval of <b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>'s AD drug Aduhelm. Simufilam doesn't work the same way as Aduhelm -- the latter focuses on removing amyloid plaques in the brain (some experts believe the buildup of the beta-amyloid protein is one of the causes of the disease). Meanwhile, simufilam is designed to restore the normal shape and function of filamin A, a protein in the brain which, in an altered form, is thought to be linked to AD.</p>\n<p>So what makes Cassava Sciences a risky stock to buy?</p>\n<p>Before the approval of Biogen's Aduhelm, there have been a long list of failed attempts at developing successful treatments for AD -- and some of these potential medicines had also produced great results in phase 2 studies. Aduhelm became the first AD drug approved since 2003. And even then, some experts believe this decision by the U.S. Food and Drug Administration (FDA) was a bad one.</p>\n<p>At least three members of an independent panel convened last year by the regulatory body to discuss Aduhelm have resigned from their roles following the drug's approval. Potential failure from clinical trials is always a risk biotech investors have to worry about. But in this case, the risk seems significantly higher than normal -- though&nbsp;that also means the potential rewards could be huge.</p>\n<p>Cassava Sciences said it would initiate a phase 3 study for its lead candidate in the second half of the year. The trial will \"evaluate disease-modifying effects of simufilam in Alzheimer's disease.\" Results could come in sometime next year. If they are positive, expect Cassava Sciences shares to soar. But if they are negative, the company's stock could fall off a cliff. <a href=\"https://laohu8.com/S/ISBC\">Investors</a> comfortable with the risk should consider initiating a (small) position in this healthcare stock.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Risk, High-Reward Stocks That Could Go to the Moon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Risk, High-Reward Stocks That Could Go to the Moon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/22/2-high-risk-high-reward-stocks-that-could-go-to-th/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There is no such thing as a risk-free investment in the stock market (or anywhere else, for that matter). However, some carry more risks than others. Many investors choose to stay away from those ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/2-high-risk-high-reward-stocks-that-could-go-to-th/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc"},"source_url":"https://www.fool.com/investing/2021/07/22/2-high-risk-high-reward-stocks-that-could-go-to-th/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153755876","content_text":"There is no such thing as a risk-free investment in the stock market (or anywhere else, for that matter). However, some carry more risks than others. Many investors choose to stay away from those companies that seem too much like longshots.\nBut others actively seek out those stocks that the market characterizes as too risky, as the potential rewards are often mouthwatering. If you belong to the latter group, here are two stocks that are a bit on the risky side, but could deliver huge gains if their respective prospects pan out: Planet 13 Holdings (OTC:PLNH.F) and Cassava Sciences (NASDAQ:SAVA).\n\nPLNHF data by YCharts\n1. Planet 13 Holdings\nWall Street analyst Owen Bennett recently called the U.S. marijuana industry a \"generational wealth opportunity.\" Whether you agree with the exact wording of this assessment or not, there is no denying that many pot stocks do offer massive growth potential. And among these companies, Planet 13 Holdings arguably has one of the most innovative business models.\nThe company isn't content with selling cannabis products. Instead, Planet 13 offers its customers a whole experience in its superstore, located on the popular Las Vegas Strip. Cannabis enthusiasts can witness firsthand the company's cannabis production process, purchase various marijuana products, and relax in the restaurant located right inside.\nWith a growing number of people fully vaccinated against COVID-19, foot traffic and tourism in Las Vegas are picking up, and Planet 13 is benefiting. The pot company reported record monthly revenue of $9.7 million in March. It went on to beat that record in April when it racked up $10.7 million in revenue. It beat that record once again in May with monthly revenue of $11.2 million.\nPlanet 13 recently opened another superstore in California, the largest U.S. state by population. The company has ambitions to open more of these cannabis-focused entertainment complexes in major cities in the U.S., including New York City, Washington D.C., and Miami.\nThis master plan isn't guaranteed to work. The cannabis industry in the U.S. is very competitive, with several companies expanding their footprints across more than a dozen states. Some of these companies generate quarterly revenue and profits much higher than those of Planet 13. Also, opening these new stores in other states will cost money, and will come with additional expenses once they are operational.\nManagement's goal of opening more than eight new superstores in the next five years might be doable, and the company is betting that these stores will see the same success as the one in Las Vegas -- which is by no means a sure bet. Planet 13 remains a small-cap company with a market cap of just $1.2 billion, and that's after its shares soared by 184% in the past year.\nIf Planet 13 goes on to execute its long-term plan, those who purchase this cannabis stock today will be glad they did so down the road.\n\nImage source: Getty Images\n2. Cassava Sciences\nShares of clinical-stage biopharma company Cassava Sciences are up by a cool 3,285% in the past year. What's behind this performance? The drugmaker's leading pipeline candidate and investigational Alzheimer's disease (AD) drug, simufilam. This medicine has produced promising data in clinical trials. In a phase 2b study, the results of which Cassava Sciences announced in September 2020, simufilam was shown to improve several biomarkers of AD in patients with the disease.\nAccording to the company, \"the ability to improve multiple biomarkers from distinct biological pathways with one drug has never been shown before in patients with Alzheimer's disease.\" In early February the company also announced results of an interim analysis of an open-label study for simufilam. The medicine successfully improved AD patients' cognition and behavior.\nEven though these results are encouraging in and of themselves, investors have also taken interest in Cassava Sciences because of the recent controversial approval of Biogen's AD drug Aduhelm. Simufilam doesn't work the same way as Aduhelm -- the latter focuses on removing amyloid plaques in the brain (some experts believe the buildup of the beta-amyloid protein is one of the causes of the disease). Meanwhile, simufilam is designed to restore the normal shape and function of filamin A, a protein in the brain which, in an altered form, is thought to be linked to AD.\nSo what makes Cassava Sciences a risky stock to buy?\nBefore the approval of Biogen's Aduhelm, there have been a long list of failed attempts at developing successful treatments for AD -- and some of these potential medicines had also produced great results in phase 2 studies. Aduhelm became the first AD drug approved since 2003. And even then, some experts believe this decision by the U.S. Food and Drug Administration (FDA) was a bad one.\nAt least three members of an independent panel convened last year by the regulatory body to discuss Aduhelm have resigned from their roles following the drug's approval. Potential failure from clinical trials is always a risk biotech investors have to worry about. But in this case, the risk seems significantly higher than normal -- though that also means the potential rewards could be huge.\nCassava Sciences said it would initiate a phase 3 study for its lead candidate in the second half of the year. The trial will \"evaluate disease-modifying effects of simufilam in Alzheimer's disease.\" Results could come in sometime next year. If they are positive, expect Cassava Sciences shares to soar. But if they are negative, the company's stock could fall off a cliff. Investors comfortable with the risk should consider initiating a (small) position in this healthcare stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159472506,"gmtCreate":1624978577105,"gmtModify":1631889891280,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","text":"$NIO Inc.(NIO)$[Miser] [Miser] [Miser]","images":[{"img":"https://static.tigerbbs.com/c71510cff390968cf52d2f909c1b49f9","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159472506","isVote":1,"tweetType":1,"viewCount":218,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":159478492,"gmtCreate":1624978507716,"gmtModify":1631889891287,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"Waiting for below&nbsp;$20","listText":"Waiting for below&nbsp;$20","text":"Waiting for below $20","images":[{"img":"https://static.tigerbbs.com/d13900ebf95ba98e9c5cf77a09cbea9b","width":"750","height":"2320"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159478492","isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150811111,"gmtCreate":1624892432233,"gmtModify":1631889891288,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;$50 tonight","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;$50 tonight","text":"$NIO Inc.(NIO)$[Miser] $50 tonight","images":[{"img":"https://static.tigerbbs.com/c362e6005baec74dd0f915cdeb7a57fd","width":"750","height":"1224"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150811111","isVote":1,"tweetType":1,"viewCount":466,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150810288,"gmtCreate":1624892341544,"gmtModify":1631889891291,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"giggle&nbsp;","listText":"giggle&nbsp;","text":"giggle","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150810288","repostId":"2146027870","repostType":4,"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150837286,"gmtCreate":1624892309345,"gmtModify":1631889891291,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/150837286","repostId":"1129950691","repostType":4,"repost":{"id":"1129950691","kind":"news","pubTimestamp":1624891529,"share":"https://www.laohu8.com/m/news/1129950691?lang=&edition=full","pubTime":"2021-06-28 22:45","market":"us","language":"en","title":"The Fed’s inflation view could drag the economy into recession, El-Erian warns","url":"https://stock-news.laohu8.com/highlight/detail?id=1129950691","media":"CNBC","summary":"KEY POINTS\n\nFed officials are underestimating inflation and risking another recession, Mohamed El-Er","content":"<div>\n<p>KEY POINTS\n\nFed officials are underestimating inflation and risking another recession, Mohamed El-Erian told CNBC on Monday.\n“Every day I see evidence of inflation not being transitory, and I have ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/28/el-erian-says-the-fed-is-behind-on-inflation-and-risks-another-recession-if-it-is-forced-to-catch-up.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Fed’s inflation view could drag the economy into recession, El-Erian warns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Fed’s inflation view could drag the economy into recession, El-Erian warns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 22:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/28/el-erian-says-the-fed-is-behind-on-inflation-and-risks-another-recession-if-it-is-forced-to-catch-up.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nFed officials are underestimating inflation and risking another recession, Mohamed El-Erian told CNBC on Monday.\n“Every day I see evidence of inflation not being transitory, and I have ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/28/el-erian-says-the-fed-is-behind-on-inflation-and-risks-another-recession-if-it-is-forced-to-catch-up.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.cnbc.com/2021/06/28/el-erian-says-the-fed-is-behind-on-inflation-and-risks-another-recession-if-it-is-forced-to-catch-up.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1129950691","content_text":"KEY POINTS\n\nFed officials are underestimating inflation and risking another recession, Mohamed El-Erian told CNBC on Monday.\n“Every day I see evidence of inflation not being transitory, and I have concern that the Fed is falling behind,” he said.\nCentral bank leaders insist that the recent round of inflation will subside once short-term supply chain bottlenecks clear and 2020 data fades from comparisons.\n\nFederal Reserve officials are underestimating inflation and risking that the U.S. could fall into another recession, Mohamed El-Erian, the Allianz chief economic advisor, told CNBC on Monday.\nCentral bank leaders insist that the recent round of price pressures will subside once short-term supply chain bottlenecks clear and the 2020 economic shutdown period is no longer part of the year-over-year comparisons.\nBut El-Erian said he sees growing evidence that the Fed is wrong.\n“I have concerns about the inflation story,” he told CNBC’s Becky Quick during a “Squawk Box” interview. “Every day I see evidence of inflation not being transitory, and I have concern that the Fed is falling behind and that it may have to play catch-up, and history makes you very uncomfortable if you end up in a world in which the Fed has to play catch-up.”\nIf the Fed does fall into that position, it may have to raise interest rates and otherwise tighten monetary policy sooner than it would like.\n“Normally, we end up with a recession because you have to slam on the brakes as opposed to slowly taking your foot off the accelerator, which is what believe is going to happen,” El-Erian said.\nThe economy is still technically in a recession that began in February 2020, according to the National Bureau of Economic Research, considered the official arbiter in such matters. However, real GDP is just a shade below where it was when the downturn started and is likely to pass that level when the second quarter data comes in.\nInflation, though, has thwarted recoveries in the past, and recent data tell conflicting stories about the current pace.\nThe Fed’s favorite gauge, the personal consumption expenditures price index excluding the volatile food and energy sectors, in May rose 3.4% from a year ago, the highest level since 1992 an well above the central bank’s 2% target.\nThat came after a 5% increase in the consumer price indexand a6.6% burst in the producer price index, both well higher than anything the U.S. has seen since at least before the financial crisis.\nBut much of the price pressures have come in areas particularly germane to the economic recovery – used car prices, air fares, hotel prices and the like.\nWhile Fed officials see those factors abating in the coming months, El-Erian said he’s not so sure, even if the financial markets don’t seem to care.\n“If you were actually to look at the numbers on inflation, you would start having serious doubts in your mind as to how transitory inflation is,” El-Erian said. “But as long as the Fed believes it’s transitory, that is what matters for markets.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126181559,"gmtCreate":1624547575071,"gmtModify":1631889891299,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"[Glance]&nbsp;","listText":"[Glance]&nbsp;","text":"[Glance]","images":[{"img":"https://static.tigerbbs.com/f96a3fd5594599594dd744ab43b84bcc","width":"750","height":"2320"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126181559","isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":150811111,"gmtCreate":1624892432233,"gmtModify":1631889891288,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;$50 tonight","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;$50 tonight","text":"$NIO Inc.(NIO)$[Miser] $50 tonight","images":[{"img":"https://static.tigerbbs.com/c362e6005baec74dd0f915cdeb7a57fd","width":"750","height":"1224"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150811111","isVote":1,"tweetType":1,"viewCount":466,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150837286,"gmtCreate":1624892309345,"gmtModify":1631889891291,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/150837286","repostId":"1129950691","repostType":4,"isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804335985,"gmtCreate":1627920967347,"gmtModify":1631889891272,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>$$$","listText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>$$$","text":"$XPeng Inc.(XPEV)$$$$","images":[{"img":"https://static.tigerbbs.com/72e0fa37cc7f2667fb941564466feb83","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804335985","isVote":1,"tweetType":1,"viewCount":131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":159472506,"gmtCreate":1624978577105,"gmtModify":1631889891280,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","text":"$NIO Inc.(NIO)$[Miser] [Miser] [Miser]","images":[{"img":"https://static.tigerbbs.com/c71510cff390968cf52d2f909c1b49f9","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159472506","isVote":1,"tweetType":1,"viewCount":218,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150810288,"gmtCreate":1624892341544,"gmtModify":1631889891291,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"giggle&nbsp;","listText":"giggle&nbsp;","text":"giggle","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150810288","repostId":"2146027870","repostType":4,"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803999340,"gmtCreate":1627399466680,"gmtModify":1631889891276,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/803999340","repostId":"2154961091","repostType":2,"isVote":1,"tweetType":1,"viewCount":381,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172537894,"gmtCreate":1626965686918,"gmtModify":1631889891280,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"Gyghhhhh","listText":"Gyghhhhh","text":"Gyghhhhh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172537894","repostId":"2153755876","repostType":4,"repost":{"id":"2153755876","kind":"highlight","pubTimestamp":1626959340,"share":"https://www.laohu8.com/m/news/2153755876?lang=&edition=full","pubTime":"2021-07-22 21:09","market":"us","language":"en","title":"2 High-Risk, High-Reward Stocks That Could Go to the Moon","url":"https://stock-news.laohu8.com/highlight/detail?id=2153755876","media":"Motley Fool","summary":"Risk-averse investors may want to look elsewhere.","content":"<p>There is no such thing as a risk-free investment in the stock market (or anywhere else, for that matter). However, some carry more risks than others. Many investors choose to stay away from those companies that seem too much like longshots.</p>\n<p>But others actively seek out those stocks that the market characterizes as too risky, as the potential rewards are often mouthwatering. If you belong to the latter group, here are two stocks that are a bit on the risky side, but could deliver huge gains if their respective prospects pan out: <b>Planet 13 Holdings</b> (OTC:PLNH.F) and <b>Cassava Sciences</b> (NASDAQ:SAVA).</p>\n<p><img src=\"https://static.tigerbbs.com/74a895bc6e17c8f58a2b42d63ee986c8\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>PLNHF data by YCharts</p>\n<h3>1. Planet 13 Holdings</h3>\n<p>Wall Street analyst Owen Bennett recently called the U.S. marijuana industry a \"generational wealth opportunity.\" Whether you agree with the exact wording of this assessment or not, there is no denying that many pot stocks do offer massive growth potential. And among these companies, Planet 13 Holdings arguably has <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most innovative business models.</p>\n<p>The company isn't content with selling cannabis products. Instead, Planet 13 offers its customers a whole experience in its superstore, located on the popular Las Vegas Strip. Cannabis enthusiasts can witness firsthand the company's cannabis production process, purchase various marijuana products, and relax in the restaurant located right inside.</p>\n<p>With a growing number of people fully vaccinated against COVID-19, foot traffic and tourism in Las Vegas are picking up, and Planet 13 is benefiting. The pot company reported record monthly revenue of $9.7 million in March. It went on to beat that record in April when it racked up $10.7 million in revenue. It beat that record once again in May with monthly revenue of $11.2 million.</p>\n<p>Planet 13 recently opened another superstore in California, the largest U.S. state by population. The company has ambitions to open more of these cannabis-focused entertainment complexes in major cities in the U.S., including <a href=\"https://laohu8.com/S/NWY\">New York</a> <a href=\"https://laohu8.com/S/CHCO\">City</a>, <a href=\"https://laohu8.com/S/WASH\">Washington</a> D.C., and Miami.</p>\n<p>This master plan isn't guaranteed to work. The cannabis industry in the U.S. is very competitive, with several companies expanding their footprints across more than a dozen states. Some of these companies generate quarterly revenue and profits much higher than those of Planet 13. Also, opening these new stores in other states will cost money, and will come with additional expenses once they are operational.</p>\n<p>Management's goal of opening more than eight new superstores in the next five years might be doable, and the company is betting that these stores will see the same success as the <a href=\"https://laohu8.com/S/AONE.U\">one</a> in Las Vegas -- which is by no means a sure bet. Planet 13 remains a small-cap company with a market cap of just $1.2 billion, and that's after its shares soared by 184% in the past year.</p>\n<p>If Planet 13 goes on to execute its long-term plan, those who purchase this cannabis stock today will be glad they did so down the road.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F634051%2Fmature-person-sits-in-a-red-chair-in-front-of-a-large-window-contemplating-something-while-looking-at-a-tablet.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"465\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images</p>\n<h3>2. Cassava Sciences</h3>\n<p>Shares of clinical-stage biopharma company Cassava Sciences are up by a cool 3,285% in the past year. What's behind this performance? The drugmaker's leading pipeline candidate and investigational Alzheimer's disease (AD) drug, simufilam. This medicine has produced promising data in clinical trials. In a phase 2b study, the results of which Cassava Sciences announced in September 2020, simufilam was shown to improve several biomarkers of AD in patients with the disease.</p>\n<p>According to the company, \"the ability to improve&nbsp;multiple biomarkers from distinct biological pathways with one drug has never been shown before in patients with Alzheimer's disease.\" In early February the company also announced results of an interim analysis of an open-label study for simufilam. The medicine successfully improved AD patients' cognition and behavior.</p>\n<p>Even though these results are encouraging in and of themselves, investors have also taken interest in Cassava Sciences because of the recent controversial approval of <b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>'s AD drug Aduhelm. Simufilam doesn't work the same way as Aduhelm -- the latter focuses on removing amyloid plaques in the brain (some experts believe the buildup of the beta-amyloid protein is one of the causes of the disease). Meanwhile, simufilam is designed to restore the normal shape and function of filamin A, a protein in the brain which, in an altered form, is thought to be linked to AD.</p>\n<p>So what makes Cassava Sciences a risky stock to buy?</p>\n<p>Before the approval of Biogen's Aduhelm, there have been a long list of failed attempts at developing successful treatments for AD -- and some of these potential medicines had also produced great results in phase 2 studies. Aduhelm became the first AD drug approved since 2003. And even then, some experts believe this decision by the U.S. Food and Drug Administration (FDA) was a bad one.</p>\n<p>At least three members of an independent panel convened last year by the regulatory body to discuss Aduhelm have resigned from their roles following the drug's approval. Potential failure from clinical trials is always a risk biotech investors have to worry about. But in this case, the risk seems significantly higher than normal -- though&nbsp;that also means the potential rewards could be huge.</p>\n<p>Cassava Sciences said it would initiate a phase 3 study for its lead candidate in the second half of the year. The trial will \"evaluate disease-modifying effects of simufilam in Alzheimer's disease.\" Results could come in sometime next year. If they are positive, expect Cassava Sciences shares to soar. But if they are negative, the company's stock could fall off a cliff. <a href=\"https://laohu8.com/S/ISBC\">Investors</a> comfortable with the risk should consider initiating a (small) position in this healthcare stock.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Risk, High-Reward Stocks That Could Go to the Moon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Risk, High-Reward Stocks That Could Go to the Moon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/22/2-high-risk-high-reward-stocks-that-could-go-to-th/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There is no such thing as a risk-free investment in the stock market (or anywhere else, for that matter). However, some carry more risks than others. Many investors choose to stay away from those ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/2-high-risk-high-reward-stocks-that-could-go-to-th/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc"},"source_url":"https://www.fool.com/investing/2021/07/22/2-high-risk-high-reward-stocks-that-could-go-to-th/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153755876","content_text":"There is no such thing as a risk-free investment in the stock market (or anywhere else, for that matter). However, some carry more risks than others. Many investors choose to stay away from those companies that seem too much like longshots.\nBut others actively seek out those stocks that the market characterizes as too risky, as the potential rewards are often mouthwatering. If you belong to the latter group, here are two stocks that are a bit on the risky side, but could deliver huge gains if their respective prospects pan out: Planet 13 Holdings (OTC:PLNH.F) and Cassava Sciences (NASDAQ:SAVA).\n\nPLNHF data by YCharts\n1. Planet 13 Holdings\nWall Street analyst Owen Bennett recently called the U.S. marijuana industry a \"generational wealth opportunity.\" Whether you agree with the exact wording of this assessment or not, there is no denying that many pot stocks do offer massive growth potential. And among these companies, Planet 13 Holdings arguably has one of the most innovative business models.\nThe company isn't content with selling cannabis products. Instead, Planet 13 offers its customers a whole experience in its superstore, located on the popular Las Vegas Strip. Cannabis enthusiasts can witness firsthand the company's cannabis production process, purchase various marijuana products, and relax in the restaurant located right inside.\nWith a growing number of people fully vaccinated against COVID-19, foot traffic and tourism in Las Vegas are picking up, and Planet 13 is benefiting. The pot company reported record monthly revenue of $9.7 million in March. It went on to beat that record in April when it racked up $10.7 million in revenue. It beat that record once again in May with monthly revenue of $11.2 million.\nPlanet 13 recently opened another superstore in California, the largest U.S. state by population. The company has ambitions to open more of these cannabis-focused entertainment complexes in major cities in the U.S., including New York City, Washington D.C., and Miami.\nThis master plan isn't guaranteed to work. The cannabis industry in the U.S. is very competitive, with several companies expanding their footprints across more than a dozen states. Some of these companies generate quarterly revenue and profits much higher than those of Planet 13. Also, opening these new stores in other states will cost money, and will come with additional expenses once they are operational.\nManagement's goal of opening more than eight new superstores in the next five years might be doable, and the company is betting that these stores will see the same success as the one in Las Vegas -- which is by no means a sure bet. Planet 13 remains a small-cap company with a market cap of just $1.2 billion, and that's after its shares soared by 184% in the past year.\nIf Planet 13 goes on to execute its long-term plan, those who purchase this cannabis stock today will be glad they did so down the road.\n\nImage source: Getty Images\n2. Cassava Sciences\nShares of clinical-stage biopharma company Cassava Sciences are up by a cool 3,285% in the past year. What's behind this performance? The drugmaker's leading pipeline candidate and investigational Alzheimer's disease (AD) drug, simufilam. This medicine has produced promising data in clinical trials. In a phase 2b study, the results of which Cassava Sciences announced in September 2020, simufilam was shown to improve several biomarkers of AD in patients with the disease.\nAccording to the company, \"the ability to improve multiple biomarkers from distinct biological pathways with one drug has never been shown before in patients with Alzheimer's disease.\" In early February the company also announced results of an interim analysis of an open-label study for simufilam. The medicine successfully improved AD patients' cognition and behavior.\nEven though these results are encouraging in and of themselves, investors have also taken interest in Cassava Sciences because of the recent controversial approval of Biogen's AD drug Aduhelm. Simufilam doesn't work the same way as Aduhelm -- the latter focuses on removing amyloid plaques in the brain (some experts believe the buildup of the beta-amyloid protein is one of the causes of the disease). Meanwhile, simufilam is designed to restore the normal shape and function of filamin A, a protein in the brain which, in an altered form, is thought to be linked to AD.\nSo what makes Cassava Sciences a risky stock to buy?\nBefore the approval of Biogen's Aduhelm, there have been a long list of failed attempts at developing successful treatments for AD -- and some of these potential medicines had also produced great results in phase 2 studies. Aduhelm became the first AD drug approved since 2003. And even then, some experts believe this decision by the U.S. Food and Drug Administration (FDA) was a bad one.\nAt least three members of an independent panel convened last year by the regulatory body to discuss Aduhelm have resigned from their roles following the drug's approval. Potential failure from clinical trials is always a risk biotech investors have to worry about. But in this case, the risk seems significantly higher than normal -- though that also means the potential rewards could be huge.\nCassava Sciences said it would initiate a phase 3 study for its lead candidate in the second half of the year. The trial will \"evaluate disease-modifying effects of simufilam in Alzheimer's disease.\" Results could come in sometime next year. If they are positive, expect Cassava Sciences shares to soar. But if they are negative, the company's stock could fall off a cliff. Investors comfortable with the risk should consider initiating a (small) position in this healthcare stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159478492,"gmtCreate":1624978507716,"gmtModify":1631889891287,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"Waiting for below&nbsp;$20","listText":"Waiting for below&nbsp;$20","text":"Waiting for below $20","images":[{"img":"https://static.tigerbbs.com/d13900ebf95ba98e9c5cf77a09cbea9b","width":"750","height":"2320"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159478492","isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":126181559,"gmtCreate":1624547575071,"gmtModify":1631889891299,"author":{"id":"3586648044185069","authorId":"3586648044185069","name":"Tyh1","avatar":"https://static.tigerbbs.com/b79bc27d4238648f993856e3db05583b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586648044185069","authorIdStr":"3586648044185069"},"themes":[],"htmlText":"[Glance]&nbsp;","listText":"[Glance]&nbsp;","text":"[Glance]","images":[{"img":"https://static.tigerbbs.com/f96a3fd5594599594dd744ab43b84bcc","width":"750","height":"2320"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126181559","isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}